Aurora, Colorado 80045


Purpose:

This protocol addresses a central hypothesis that fibrostenotic Eosinophilic Esophagitis (EoE) is characterized by abnormal esophageal structure and compliance compared to non fibrostenotic EoE and that distinctive cellular and molecular profiles predict the fibrostenotic phenotype. This study aims to define and assess the changes that occur in the structure and dynamics of the esophageal wall in pediatric Eosinophilic Esophagitis along with characterizing the histologic and molecular patterns in fibrostenotic EoE.


Criteria:

Inclusion Criteria: - Scheduled to undergo a clinical upper endoscopy with biopsy Exclusion Criteria: - Known connective tissue disorder - Increased risk of bleeding - Inflammatory bowel disease, celiac disease, eosinophilic gastroenteritis, or any autoimmune disease - Other esophageal disease including known achalasia; history of caustic ingestion, esophageal surgery esophageal stricture for other known reason or other esophageal injury. - Use of oral or intravenous steroids in the preceding 60 days. (Swallowed topical fluticasone, budesonide, etc not included as exclusion criteria.)


NCT ID:

NCT02453126


Primary Contact:

Principal Investigator
Calies Menard-Katcher, MD
University of Colorado/Childrens Hospital Colorado

Faria Ahmed
Phone: 720-777-2797
Email: faria.ahmed@childrenscolorado.org


Backup Contact:

N/A


Location Contact:

Aurora, Colorado 80045
United States

Faria Ahmed
Phone: 720-777-2797
Email: faria.ahmed@childrenscolorado.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.